MetLife Investment Management’s Tango Therapeutics TNGX Stock Holding History

MetLife Investment Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.27M	Buy	60,694 +1,002	+2%	+$13.9K	0.01%	1288
2025 Q4	$529K	Buy	59,692 +11,966	+25%	+$103K	﹤0.01%	1771
2025 Q3	$401K	Hold	47,726	–	–	﹤0.01%	1915
2025 Q2	$244K	Buy	+47,726	New	+$118K	﹤0.01%	2083
2025 Q1	–	Sell	-19,631	Closed	-$60.7K	–	2825
2024 Q4	$60.7K	Sell	19,631 -8,633	-31%	-$40.1K	﹤0.01%	2724
2024 Q3	$218K	Hold	28,264	–	–	﹤0.01%	2246
2024 Q2	$243K	Buy	28,264 +2,484	+10%	+$19.2K	﹤0.01%	2128
2024 Q1	$205K	Hold	25,780	–	–	﹤0.01%	2193
2023 Q4	$255K	Hold	25,780	–	–	﹤0.01%	2095
2023 Q3	$290K	Hold	25,780	–	–	﹤0.01%	1982
2023 Q2	$85.6K	Hold	25,780	–	–	﹤0.01%	2773
2023 Q1	$102K	Hold	25,780	–	–	﹤0.01%	2546
2022 Q4	$187K	Buy	+25,780	New	+$181K	﹤0.01%	2285
2022 Q3	–	Sell	-28,639	Closed	-$130K	–	2838
2022 Q2	$130K	Buy	+28,639	New	+$173K	﹤0.01%	2586

Other funds holding TNGX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

MetLife Investment Management's TNGX Position: Q1 2026 in Review

MetLife Investment Management increased its Tango Therapeutics (TNGX) stake by 1.7% in Q1 2026, buying an estimated $13.9K and bringing the position to 60,694 shares worth $1.27M. The position accounts for 0.01% of the portfolio, ranked #1288.

MetLife Investment Management first reported a position in TNGX in Q2 2022 and has held it in 14 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

MetLife Investment Management held 60,694 shares of Tango Therapeutics worth $1.27M as of Q1 2026.
MetLife Investment Management bought 1,002 Tango Therapeutics shares in Q1 2026, an estimated $13.9K.
Tango Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1288 holding.
MetLife Investment Management first reported a position in Tango Therapeutics in Q2 2022 and has held it in 14 quarters since.
194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.